Tags

Type your tag names separated by a space and hit enter

Six-day therapy with ranitidine bismuth citrate plus low-dose clarithromycin and tinidazole to cure Helicobacter pylori infection.
Hepatogastroenterology 2000 Jul-Aug; 47(34):1176-9H

Abstract

BACKGROUND/AIMS

Short-term ranitidine bismuth citrate-based triple regimens have been shown to be effective for the eradication of H. pylori. We investigated the efficacy of an eradicating therapy including ranitidine bismuth citrate, low-dose clarithromycin and tinidazole, administered for only 6 days.

METHODOLOGY

Forty-five consecutive patients, who underwent gastroscopy for symptoms and were found to be H. pylori-positive, were recruited. They received ranitidine bismuth citrate 400 mg b.i.d. plus clarithromycin 250 mg b.i.d. plus tinidazole 500 mg b.i.d., given for 6 days. The medications given in twice daily doses were taken after meals with an interval of 12 h. The H. pylori status was evaluated by means of histology and rapid urease test on admission, and by 13C-urea breath test alone 8 weeks after treatment.

RESULTS

All 45 enrolled patients completed the study. Thirty-nine of 45 patients returned H. pylori-negative (both per protocol and intention-to-treat analysis = 87%; 95% confidence interval = from 73-95%), while 6 of 45 were still H. pylori-positive (13%). Slight or mild side effects occurred in 5/45 patients (11%).

CONCLUSIONS

Ranitidine bismuth citrate-based triple therapy, containing low-dose clarithromycin and tinidazole, given for only 6 days, yielded high eradication rates with modest side effects. Regimens based on ranitidine bismuth citrate plus two antibiotics at low dosages, administered for less than 7 days, constitute highly promising strategies for eradication of H. pylori.

Authors+Show Affiliations

Department of Internal Medicine and Gastroenterology, Catholic University SC, Rome, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

11020908

Citation

Cammarota, G, et al. "Six-day Therapy With Ranitidine Bismuth Citrate Plus Low-dose Clarithromycin and Tinidazole to Cure Helicobacter Pylori Infection." Hepato-gastroenterology, vol. 47, no. 34, 2000, pp. 1176-9.
Cammarota G, Cannizzaro O, Cianci R, et al. Six-day therapy with ranitidine bismuth citrate plus low-dose clarithromycin and tinidazole to cure Helicobacter pylori infection. Hepatogastroenterology. 2000;47(34):1176-9.
Cammarota, G., Cannizzaro, O., Cianci, R., Gasbarrini, A., Pirozzi, G., & Gasbarrini, G. (2000). Six-day therapy with ranitidine bismuth citrate plus low-dose clarithromycin and tinidazole to cure Helicobacter pylori infection. Hepato-gastroenterology, 47(34), pp. 1176-9.
Cammarota G, et al. Six-day Therapy With Ranitidine Bismuth Citrate Plus Low-dose Clarithromycin and Tinidazole to Cure Helicobacter Pylori Infection. Hepatogastroenterology. 2000;47(34):1176-9. PubMed PMID: 11020908.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Six-day therapy with ranitidine bismuth citrate plus low-dose clarithromycin and tinidazole to cure Helicobacter pylori infection. AU - Cammarota,G, AU - Cannizzaro,O, AU - Cianci,R, AU - Gasbarrini,A, AU - Pirozzi,G, AU - Gasbarrini,G, PY - 2000/10/6/pubmed PY - 2001/3/3/medline PY - 2000/10/6/entrez SP - 1176 EP - 9 JF - Hepato-gastroenterology JO - Hepatogastroenterology VL - 47 IS - 34 N2 - BACKGROUND/AIMS: Short-term ranitidine bismuth citrate-based triple regimens have been shown to be effective for the eradication of H. pylori. We investigated the efficacy of an eradicating therapy including ranitidine bismuth citrate, low-dose clarithromycin and tinidazole, administered for only 6 days. METHODOLOGY: Forty-five consecutive patients, who underwent gastroscopy for symptoms and were found to be H. pylori-positive, were recruited. They received ranitidine bismuth citrate 400 mg b.i.d. plus clarithromycin 250 mg b.i.d. plus tinidazole 500 mg b.i.d., given for 6 days. The medications given in twice daily doses were taken after meals with an interval of 12 h. The H. pylori status was evaluated by means of histology and rapid urease test on admission, and by 13C-urea breath test alone 8 weeks after treatment. RESULTS: All 45 enrolled patients completed the study. Thirty-nine of 45 patients returned H. pylori-negative (both per protocol and intention-to-treat analysis = 87%; 95% confidence interval = from 73-95%), while 6 of 45 were still H. pylori-positive (13%). Slight or mild side effects occurred in 5/45 patients (11%). CONCLUSIONS: Ranitidine bismuth citrate-based triple therapy, containing low-dose clarithromycin and tinidazole, given for only 6 days, yielded high eradication rates with modest side effects. Regimens based on ranitidine bismuth citrate plus two antibiotics at low dosages, administered for less than 7 days, constitute highly promising strategies for eradication of H. pylori. SN - 0172-6390 UR - https://www.unboundmedicine.com/medline/citation/11020908/Six_day_therapy_with_ranitidine_bismuth_citrate_plus_low_dose_clarithromycin_and_tinidazole_to_cure_Helicobacter_pylori_infection_ L2 - https://medlineplus.gov/helicobacterpyloriinfections.html DB - PRIME DP - Unbound Medicine ER -